Cargando…

Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications

Despite recent advances in heart failure (HF) management, the risk of death and hospitalizations remains high in the long term. HF is characterized by endothelial dysfunction, inflammation and increased oxidative stress, due to a reduction in the activity of the nitric oxide (NO)-soluble guanylate c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vannuccini, Francesca, Campora, Alessandro, Barilli, Maria, Palazzuoli, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598881/ https://www.ncbi.nlm.nih.gov/pubmed/36289733 http://dx.doi.org/10.3390/biomedicines10102471

Ejemplares similares

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

ANMCO position paper on vericiguat use in heart failure: from evidence to place in therapy
por: Di Fusco, Stefania Angela, et al.
Publicado: (2023)

Chronic heart failure: the role of di vericiguat
por: Caminiti, Giuseppe, et al.
Publicado: (2023)

Vericiguat: A New Hope for Heart Failure Patients
por: Chiles, Raquel, et al.
Publicado: (2022)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Emerging concepts in heart failure management and treatment: focus on vericiguat
por: Kaplinsky, Edgardo, et al.
Publicado: (2023)

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
por: Falco, Luigi, et al.
Publicado: (2023)

A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure
por: Sahana, Urjosee, et al.
Publicado: (2023)

Efficacy and safety of vericiguat in heart failure: a meta-analysis
por: Ma, Jianhua, et al.
Publicado: (2023)

Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence
por: Palazzuoli, Alberto, et al.
Publicado: (2022)

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
por: González-Juanatey, José Ramón, et al.
Publicado: (2023)

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
por: Ruehs, Hauke, et al.
Publicado: (2021)

Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
por: Oh, Jaewon, et al.
Publicado: (2022)

The efficacy of vericiguat for heart failure: A meta-analysis of randomized controlled trials
por: Ma, Guofang, et al.
Publicado: (2023)

Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
por: Nakamura, Makiko, et al.
Publicado: (2023)

Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction?
por: Hammer, Andreas, et al.
Publicado: (2023)

Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations
por: Kassis-George, Hayah, et al.
Publicado: (2022)

Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial
por: Voors, Adriaan A., et al.
Publicado: (2021)

Sacubitril/valsartan, sodium‐glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy
por: Norre, Tobias, et al.
Publicado: (2022)

Dosing Challenges and Benefits of Vericiguat in a Patient With Decompensated Heart Failure: A Case Report
por: Speranza-Sánchez, Mario, et al.
Publicado: (2023)

The clinical development of sGC modulators, riociguat and vericiguat
por: Misselwitz, Frank
Publicado: (2015)

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
por: Senni, Michele, et al.
Publicado: (2022)

Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event
por: Alsumali, Adnan, et al.
Publicado: (2021)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
por: Alsumali, Adnan, et al.
Publicado: (2021)

Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Recent advances in pharmacological treatment of heart failure
por: Iacoviello, Massimo, et al.
Publicado: (2021)

Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”
por: Gandjour, Afschin
Publicado: (2022)

Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature
por: Palazzuoli, Alberto, et al.
Publicado: (2023)

Cardiac congestion assessed by natriuretic peptides oversimplifies the definition and treatment of heart failure
por: Palazzuoli, Alberto, et al.
Publicado: (2021)

Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF
por: Barilli, Maria, et al.
Publicado: (2022)

In-hospital Routes of Acute Heart Failure Admissions During COVID-19
por: Ruocco, Gaetano, et al.
Publicado: (2020)

Pulmonary Congestion Assessment in Heart Failure: Traditional and New Tools
por: Pirrotta, Filippo, et al.
Publicado: (2021)

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study
por: Pieske, Burkert, et al.
Publicado: (2017)

Clinical, Laboratory and Lung Ultrasound Assessment of Congestion in Patients with Acute Heart Failure
por: Palazzuoli, Alberto, et al.
Publicado: (2022)

Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development
por: Gronda, Edoardo, et al.
Publicado: (2020)

Risk Factors and Cellular Differences in Heart Failure: The Key Role of Sex Hormones
por: Delcuratolo, Elvira, et al.
Publicado: (2023)

Impact of vericiguat on baroreflex-mediated sympathetic circulatory regulation: An open-loop analysis
por: Yokoi, Aimi, et al.
Publicado: (2023)

Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults
por: Boettcher, Michael, et al.
Publicado: (2023)

Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney
por: Palazzuoli, Alberto, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hmskt4fjbeo2g3e7kn9rhg0bu5